BioSpace News Archive

Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, announced positive interim clinical data from the ongoing Phase 1 study of its lead asset, ELI-002, an investigational therapeutic cancer immunotherapy.

Allogene Therapeutics, Inc. presented long-term follow up data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory large B-cell lymphoma at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.

Cyteir Therapeutics, Inc. presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster titled “Phase 1 Results of CYT-0851, a Monocarboxylate Transporter Inhibitor, in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors” at the 2023 American Society of Clinical Oncology annual meeting in Chicago, Illinois.

Exai Bio announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample.

Merck, known as MSD outside of the United States and Canada, announced positive results from the pivotal Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen, which includes treatment before surgery and after surgery, for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced positive lead-in data from its ongoing Phase 3 PEAK trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with Gastrointestinal Stromal Tumors.

Gracell Biotechnologies Inc. presented long-term follow-up data from a multicenter study evaluating GC012F, a B-cell maturation antigen and CD19 dual-targeted autologous CAR-T therapeutic candidate, in RRMM during an oral abstract presentation at the 2023 American Society of Clinical Oncology Annual Meeting.

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that new data on DecisionDx®-Melanoma and DecisionDx®-UM will be shared during the 2023 American Society of Clinical Oncology Annual Meeting, taking place June 2-6.

Intensity Therapeutics, Inc. announced that data from its ongoing phase 1/2 clinical trial demonstrating the efficacy and tolerability of INT230-6, either as monotherapy or in combination with ipilimumab in patients with relapsed, refractory and metastatic sarcomas, will be presented this afternoon at the 2023 American Society of Clinical Oncology Annual Meeting being held in Chicago and virtually from June 2-6, 2023.

Headquartered in Shanghai China, Sanyou Biopharmaceuticals Co., Ltd. is a world-leading national high-tech biotechnology enterprise focusing on R&D and services of innovative biological drugs.